Tech Company Financing Transactions
Quidditas Therapeutics Funding Round
On 5/12/2025, Quidditas Therapeutics secured $3 million in funding from iXLife Capital, Key Ventures and Research in Wallonia.
Transaction Overview
Company Name
Announced On
5/12/2025
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to further enhance its R&D efforts and the development of its recombination-based genome editing technology.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
23, rue des bourguignons
Montlhéry, 91310
France
Montlhéry, 91310
France
Phone
Undisclosed
Email Address
Overview
A constant effort needs to be maintained to propose new treatments for genetic disorders. In this context, QUIDDITAS seeks to propel its flagship technology GREAT as a reference in the genome editing field. Our major concern is to offer therapeutic responses to diseases currently considered as uncurable and bring hope for patients through broadly available off-the-shelf therapies, with the dual consideration of security and transparency.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
François Cherbonneau
Chief Operating Officer
Aurore Prunevieille
Browse more venture capital transactions:
Prev: 5/12/2025: Axe venture capital transaction
Next: 5/12/2025: Stash venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs